In our analysis, after correcting for HR expression, HER2-positive breast cancer still showed significantly different mutations compared with HER2-low and HER2-zero breast cancer, but only marginal differences were found between HER2-low and HER2-zero tumors. This evidence concerns the gene ERBB2 and breast cancer.